icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
Feb 19-22 2023
Back grey_arrow_rt.gif
 
 
 
Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study
 
 
  CROI 2023 Feb 20-23
 
Takeki Uehara1, Hiroshi Yotsuyanagi2, Norio Ohmagari3, Yohei Doi4, Masaya Yamato5, Takumi Imamura1, Takuhiro Sonoyama1, Takao Sanaki6, Yuko Tsuge1, Genki Ichihashi1, Hiroshi Mukae7
1. Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
2. The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
3. Disease Control and Prevention Center, National Center for Global Health, Tokyo, Japan
4. Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
5. Department of General Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan
6. Research Division, Shionogi & Co., Ltd., Osaka, Japan
7. Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

0314231

0314232

0314233

0314234

0314235